NVAX Q3 2017 Earnings — Novavax, Inc. Revenue & Financial Results | Market Cap Arena

NVAXNovavax, Inc.

$2B

Q3 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$8M+158.5% YoY

Gross Profit

$8M100.0% margin

Operating Income

-$42M-498.4% margin

Net Income

-$45M-534.1% margin

EPS (Diluted)

$-3.01

QoQ Revenue Growth

+24.1%

Cash Flow

Operating Cash Flow

-$37M

Free Cash Flow

-$38M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$334M

Total Liabilities

$408M

Stockholders' Equity

-$74M

Cash & Equivalents

$104M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$8M	$3M	+158.5%
Gross Profit	$8M	$3M	+158.5%
Operating Income	-$42M	-$63M	+34.2%
Net Income	-$45M	-$66M	+32.7%